Medicinal Plants And Biogenic Metal Oxide Nanoparticles: A Paradigm Shift To Treat Alzheimer'S Disease

Alzheimer's disease (AD) is the most prevalent form of dementia. Improving the amount of acetylcholine in the brain is an efficient way to treat the illness. The global incidence of dementia is estimated to be as high as 50 million, and it is expected to increase every 20 years until 2040, resulting in a costly burden of disease. Early-life risk factors for pathology include genes, chromosomal abnormalities, head injury, insulin resistance, and inflammation. Potentially modifiable risk factors including obesity, diabetes, hypertension, and smoking are associated with Alzheimer's disease (AD) and represent promising targets for intervention. The drugs currently being used to manage AD have various drawbacks. The chemical inhibition of cholinesterase enzymes is an effective technique for treating signal related neuropathology, and possible sources of compounds with these properties are natural products and biogenic metal oxide nanoparticles. There is a potential source of AChE and BChE inhibitors in the abundance of plants in nature, and natural goods appear to offer useful medications and templates for the development of other compounds. This dissertation represents a review of the literature on species of medicinal plants and nanomaterial related plants tested for their inhibitory action of AChE and BChE. Plant species and the plant-mediated metal oxide nanoparticles referred to are possible cholinesterase inhibitors and can assist researchers in their study of natural products that may be beneficial in the treatment of AD.